Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study
Most participants showed no clinically meaningful worsening in physical functioning after 24 weeks of darolutamide treatment, but poor agreement between tests was observed. Tools to accurately and consistently measure the impact of ARIs on physical functioning in patients with CRPC are needed.
Authors
- Jeffrey Scott Wefel (ORCID: https://orcid.org/0000-0003-3584-023X)
- Frank Verholen
- Daniel J. George (ORCID: https://orcid.org/0000-0003-1499-7203)
- Shankar Srinivasan (ORCID: https://orcid.org/0000-0002-5843-7008)
- Tomasz M. Beer (ORCID: https://orcid.org/0000-0001-5600-9993)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Kerri M. Winters‐Stone (ORCID: https://orcid.org/0000-0003-1706-8020)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Jorge Ortiz (ORCID: https://orcid.org/0000-0002-0120-8239)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Bayer (United States) (US)
- Oregon Health & Science University (US)
- Dana-Farber Cancer Institute (US)
- Bayer (Switzerland) (CH)
- Duke Medical Center (US)
- Carolina Urologic Research Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1093/oncolo/oyae287
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Bayer HealthCare